AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$61.94
pos +0.58
+0.95%
Today's Range: 61.45 - 62.24 | ABBV Avg Daily Volume: 7,358,600
Last Update: 02/23/17 - 4:00 PM EST
Volume: 8,057,187
YTD Performance: -1.26%
Open: $61.68
Previous Close: $61.36
52 Week Range: $54.01 - $68.12
Oustanding Shares: 1,593,920,285
Market Cap: 98,552,091,222
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 4 4 5 5
Moderate Buy 1 1 1 1
Hold 8 8 8 8
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.50 2.50 2.40 2.40
Latest Dividend: 0.64
Latest Dividend Yield: 4.14%
Dividend Ex-Date: 04/11/17
Price Earnings Ratio: 12.83
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
12.83 17.00 30.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
2.33% 13.02% 21.14%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.40 0.11
Net Income 15.70 0.40 0.13
EPS 15.50 0.40 0.12
Earnings for ABBV:
EBITDA 9.38B
Revenue 25.64B
Average Earnings Estimates
Qtr (03/17) Qtr (06/17) FY (12/17) FY (12/18)
Average Estimate $1.26 $1.39 $5.49 $6.49
Number of Analysts 6 6 12 10
High Estimate $1.31 $1.44 $5.53 $7.06
Low Estimate $1.23 $1.36 $5.45 $6.05
Prior Year $1.15 $1.26 $4.82 $5.49
Growth Rate (Year over Year) 9.42% 10.58% 13.88% 18.20%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Icahn may have a tough time finding interest in this behemoth.
You might want to review your holdings in the sector.
Would get drugs to market faster and possibly more cheaply.

Novice Trade: AbbVie Real Money Pro($)

Getting FDA to streamline its approval process would boost drug makers.
Carrot-stick 'arrangement' with biotech is a fair tradeoff but will produce winners and losers.
Value stocks will extend their outperformance over growth stocks that began last year.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.

Biotech Just Got Trumped Real Money Pro($)

But the 3% drop in the sector yesterday is clearly an overreaction to Trump's comments.
We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this segment of the market in 2016 and I still believe there is value here.
Overall, the next move for ABBV looks like it will be to the upside.

Columnist Conversations

The SPDR S&P Biotech ETF (XBI) was trading in a four month symmetrical triangle before it broke out o...
Join me later today as I bring back Toni Hanser to a webinar.  Toni has been away for awhile recovering f...
Here is a well defined zone to look for buy triggers against...defining the risk below it! View Char...
this is the FOURTH big winner we have booked on Apple since December. SOLD AAPL APR 135 CALL AT 4.50 (in ...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.